These findings may be translatable to individual HNSCC patients with unique TME (e.g., higher expression of CSF1/VEGF-C), and determining these multi-factorial profiles will help identify patients who may benefit from ICI therapy or other personalized therapies. Here, VEGFC is linked to head and neck squamous cell carcinoma.